The association between serious upper gastrointestinal bleeding and incident bisphosphonate use: A population-based nested cohort study

BMC Geriatrics

Volumn 13, Issue 1, 2013, Pages

  Knopp Sihota, Jennifer A ^a,b   Cummings, Greta G ^b   Homik, Joanne ^b   Voaklander, Don ^b  

^a ATHABASCA UNIVERSITY   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Adverse events; Bisphosphonates; Claims data; Osteoporosis; Upper gastrointestinal bleed

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE;

AGED; ARTICLE; CHEMICALLY INDUCED DISORDER; COHORT ANALYSIS; FEMALE; GASTROINTESTINAL HEMORRHAGE; HEALTH SURVEY; HUMAN; INCIDENCE; MALE; METHODOLOGY; RETROSPECTIVE STUDY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COHORT STUDIES; DIPHOSPHONATES; FEMALE; GASTROINTESTINAL HEMORRHAGE; HUMANS; INCIDENCE; MALE; POPULATION SURVEILLANCE; RETROSPECTIVE STUDIES;

EID: 84876988905     PISSN: None     EISSN: 14712318     Source Type: Journal    
DOI: 10.1186/1471-2318-13-36     Document Type: Article

References (60)

1. Osteoporosi appendix 2 oral prescription medications included in the analysis s prevention, diagnosis, and therapy. NIH Consensus Development Panel on Osteoporosis Prevention D, & Therapy, JAMA 2001 285 6 785 795 10.1001/jama.285.6.785 11176917
2. 2010 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada: Summary. Papaioannou A, Morin S, Cheung AM, Atkinson S, Brown JP, Feldman S, Hanley DA, Hodsman A, Jamal SA, Kaiser SM, CMAJ 2010 182 17 1864 1873 20940232
3. Clinical role of bisphosphonate therapy. Hampson G, Fogelman I, Int J Womens Health 2012 4 455 469 23071416
4. Systematic review: Comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttorp M, Mojica W, Timmer M, Alexander A, McNamara M, Ann Intern Med 2008 148 3 197 213 10.7326/0003-4819- 148-3-200802050-00198 18087050 (Pubitemid 351665507)
5. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, J Bone Miner Res 2007 22 10 1479 1491 10.1359/jbmr.0707onj 17663640 (Pubitemid 351229318)
6. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. Green J, Czanner G, Reeves G, Watson J, Wise L, Beral V, BMJ 2010 341 4444 10.1136/bmj.c4444 20813820
7. Bisphosphonate use and gastrointestinal tract cancer risk: meta-analysis of observational studies. Oh YH, Yoon C, Park SM, World J Gastroenterol 2012 18 40 5779 5788 10.3748/wjg.v18.i40.5779 23155320
8. Bisphosphonates and risk of upper gastrointestinal cancer-A case control study using the General Practice Research Database (GPRD). Wright E, Schofield PT, Seed P, Molokhia M, PLoS One 2012 7 10 47616 10.1371/journal.pone.0047616 23112825
9. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. Park-Wyllie L, Mamdani MM, Juurlink DN, JAMA 2011 305 8 783 789 10.1001/jama.2011.190 21343577
10. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. Black DM, Kelly MP, Genant HK, Palermo L, Eastell R, Bucci-Rechtweg C, Cauley J, Leung PC, Boonen S, Santora A, N Engl J Med 2010 362 19 1761 1771 10.1056/NEJMoa1001086 20335571
11. Long-term tolerability of the bisphosphonates in postmenopausal osteoporosis: A comparative review. Kherani RB, Papaioannou A, Adachi JD, Drug Saf 2002 25 11 781 790 10.2165/00002018-200225110-00003 12222989 (Pubitemid 35178634)
12. Drug injury in the upper gastrointestinal tract: Effects of alendronate. Khapra AP, Rose S, Gastrointest Endosc Clin N Am 2006 16 1 99 110 10.1016/j.giec.2006.01.002 16546026
13. Role of bisphosphonates in the management of postmenopausal osteoporosis: An update on recent safety anxieties. Hollick RJ, Reid DM, Menopause Int 2011 17 2 66 72 10.1258/mi.2011.011014 21693503
14. Safety of drugs used in the treatment of osteoporosis. McGreevy C, Williams D, Therapeutic Advances in Drug Safety 2011 2 4 159 172 10.1177/2042098611411012
15. Safety of long-term bisphosphonate therapy for the management of osteoporosis. Lewiecki EM, Drugs 2011 71 6 791 814 10.2165/11585470-000000000- 00000 21504254
16. Adverse drug reactions: Definitions, diagnosis, and management. Edwards IR, Aronson JK, Lancet 2000 356 9237 1255 1259 10.1016/S0140-6736(00)02799-9 11072960
17. Bisphosphonates in the treatment of osteoporosis: a review of their contribution and controversies. Reid IR, Skeletal Radiol 2011 40 9 1191 1196 10.1007/s00256-011-1164-9 21847749
18. Risk of upper gastrointestinal bleeding with oral bisphosphonates and non steroidal anti-inflammatory drugs: A case-control study. Etminan M, LÉVesque L, Fitzgerald JM, Brophy JM, Aliment Pharmacol Ther 2009 29 11 1188 1192 10.1111/j.1365-2036.2009.03989.x 19298582
19. Gastric and duodenal safety of daily alendronate. Donahue JG, Chan KA, Andrade SE, Beck A, Boles M, Buist DSM, Carey VJ, Chandler JM, Chase GA, Ettinger B, Arch Intern Med 2002 162 8 936 942 10.1001/archinte.162.8.936 11966346 (Pubitemid 34299127)
20. Gastric and esophagus events before and during treatment of osteoporosis. Vestergaard P, Schwartz K, Pinholt EM, Rejnmark L, Mosekilde L, Calcif Tissue Int 2010 86 2 110 115 10.1007/s00223-009-9323-x 19957165
21. Comparative gastrointestinal safety of weekly oral bisphosphonates. Cadarette SM, Katz JN, Brookhart MA, Starmer T, Stedman MR, Levin R, Solomon DH, Osteoporos Int 2009 20 10 1735 1747 10.1007/s00198-009-0871-8 19266138
22. PharmaCare http://www.popdata.bc.ca/data/internal/health/pharmacare
23. Population Estimates http://www.bcstats.gov.bc.ca/Home.aspx
24. Safety considerations with bisphosphonates for the treatment of osteoporosis. Strampel W, Emkey R, Civitelli R, Drug Saf 2007 30 9 755 763 10.2165/00002018-200730090-00003 17722968 (Pubitemid 47351214)
25. Discharge Abstract Database (Hospital Separations File) http://www.popdata.bc.ca/data/internal/health/dad
26. Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronate. Blumentals WA, Harris ST, Cole RE, Huang L, Silverman SL, Ann Pharmacother 2009 43 4 577 585 10.1345/aph.1L555 19318598
27. Clinic visits and hospital admissions for care of acid-related upper gastrointestinal disorders in women using alendronate for osteoporosis. Ettinger B, Pressman A, Schein J, Am J Manag Care 1998 4 10 1377 1382 10338731 (Pubitemid 28506801)
28. Pharmacoeconomic evaluation of gastrointestinal tract events during treatment with risedronate or alendronate: A retrospective study. Kane S, Borisov NN, Brixner D, Am J Manag Care 2004 10 216 S226
29. Incidence of gastrointestinal events among bisphosphonate patients in an observational setting. Miller RG, Bolognese M, Worley K, Solis A, Sheer R, Am J Manag Care 2004 10 207 S215
30. Incidence of lactic acidosis in metformin users. Stang M, Wysowski DK, Butler-Jones D, Diabetes Care 1999 22 6 925 927 10.2337/diacare.22.6.925 10372243 (Pubitemid 29241046)
31. BC Vital Statistics Death Events Registry http://www.popdata.bc.ca/data/ internal/demographic/vsdeaths
32. Incidence of serious upper gastrointestinal bleeding/perforation in the general population: Review of epidemiologic studies. Hernandez-Diaz S, Rodriguez LAG, J Clin Epidemiol 2002 55 2 157 163 10.1016/S0895-4356(01)00461-9 11809354 (Pubitemid 34051529)
33. Epidemiology of acute upper gastrointestinal bleeding. van Leerdam ME, Best Pract Res Clin Gastroenterol 2008 22 2 209 224 10.1016/j.bpg.2007.10.011 18346679 (Pubitemid 351372995)
34. Hosmer DW, Lemeshow S, Applied Logistic Regression, 2nd edn New York: John Wiley & Sons, Inc 2000
35. Systematic review of peptic ulcer disease incidence rates: do studies without validation provide reliable estimates? Lin KJ, García Rodríguez LA, Hernández-Díaz S, Pharmacoepidemiol Drug Saf 2011 20 7 718 728 10.1002/pds.2153 21626606
36. Epidemiology of hospitalization for acute upper gastrointestinal hemorrhage: A population-based study. Longstreth GF, Am J Gastroenterol 1995 90 2 206 210 7847286
37. Risk factors for hospitalized gastrointestinal bleeding among older persons. Kaplan RC, Heckbert SR, Koepsell TD, Furberg CD, Polak JF, Schoen RE, Psaty BM, For The Cardiovascular Health Study I, J Am Geriatr Soc 2001 49 2 126 133 10.1046/j.1532-5415.2001.49032.x 11207865 (Pubitemid 32207220)
38. Gastrointestinal bleeding in the elderly. Yachimski PS, Friedman LS, Nat Clin Pract Gastroenterol Hepatol 2008 5 2 80 93 18253137 (Pubitemid 351234278)
39. Adapting a clinical co-morbidity index for use with ICD-9-CM administrative databases. Deyo RA, Cherkin DC, Ciol MA, J Clin Epidemiol 1992 45 6 613 619 10.1016/0895-4356(92)90133-8 1607900
40. A new method of classifying prognostic co-morbidity in longitudinal studies: Development and validation. Charlson ME, Pompei P, Ales KL, MacKenzie CR, J Chronic Dis 1987 40 5 373 383 10.1016/0021-9681(87)90171-8 3558716 (Pubitemid 17055592)
41. Comorbidity measures for use with administrative data. Elixhauser A, Steiner C, Harris DR, Coffey RM, Med Care 1998 36 1 8 27 10.1097/00005650- 199801000-00004 9431328 (Pubitemid 128456396)
42. Medication use and falls in community-dwelling older persons. Kelly KD, Pickett W, Yiannakoulias N, Rowe BH, Schopflocher DP, Svenson L, Voaklander DC, Age Ageing 2003 32 5 503 509 10.1093/ageing/afg081 12957999 (Pubitemid 37229043)
43. Medical Services Plan (MSP) Payment Information File http://www.popdata. bc.ca/data/internal/health/msp
44. Performance of co-morbidity scores to control for confounding in epidemiologic studies using claims data. Schneeweiss S, Seeger JD, Maclure M, Wang PS, Avorn J, Glynn RJ, Am J Epidemiol 2001 154 9 854 864 10.1093/aje/154.9.854 11682368 (Pubitemid 33000813)
45. Selecting a patient characteristics index for the prediction of medical outcomes using administrative claims data. Melfi C, Holleman E, Arthur D, Katz B, J Clin Epidemiol 1995 48 7 917 926 10.1016/0895-4356(94)00202-2 7782800
46. Common comorbidity scales were similar in their ability to predict health care costs and mortality. Perkins AJ, Kroenke K, Unutzer J, Katon W, Williams JW, Hope C, Callahan CM, J Clin Epidemiol 2004 57 10 1040 1048 10.1016/j.jclinepi.2004.03.002 15528055 (Pubitemid 39446643)
47. Co-morbidity risk-adjustment strategies are comparable among persons with hip fracture. Radley DC, Gottlieb DJ, Fisher ES, Tosteson AN, J Clin Epidemiol 2008 61 6 580 587 10.1016/j.jclinepi.2007.08.001 18471662
48. Physical activity and risk of severe gastrointestinal hemorrhage in older persons. Pahor M, Guralnik JM, Salive ME, Chrischilles EA, Brown SL, Wallace RB, JAMA 1994 272 8 595 599 10.1001/jama.1994.03520080037040 8057514 (Pubitemid 24255217)
49. Reflux oesophagitis and Helicobacter pylori infection in elderly patients. Liston R, Pitt MA, Banerjee AK, Postgrad Med J 1996 72 846 221 223 10.1136/pgmj.72.846.221 8733530 (Pubitemid 26114283)
50. Changes in aetiology and clinical outcome of acute upper gastrointestinal bleeding during the last 15 years. Thomopoulos KC, Vagenas KA, Vagianos CE, Margaritis VG, Blikas AP, Katsakoulis EC, Nikolopoulou VN, Eur J Gastroenterol Hepatol 2004 16 2 177 182 10.1097/00042737-200402000-00009 15075991 (Pubitemid 39049654)
51. Esophagitis is a major cause of upper gastrointestinal hemorrhage in the elderly. Zimmerman J, Shohat V, Tsvang E, Arnon R, Safadi R, Wengrower D, Scand J Gastroenterol 1997 32 9 906 909 10.3109/00365529709011200 9299669 (Pubitemid 27382035)
52. Changing trends in acute upper-GI bleeding: a population-based study. Loperfido S, Baldo V, Piovesana E, Bellina L, Rossi K, Groppo M, Caroli A, Dal Bo N, Monica F, Fabris L, Gastrointest Endosc 2009 70 2 212 224 10.1016/j.gie.2008.10.051 19409558
53. Nonsteroidal anti-inflammatory drugs and the risk of hospitalization for acute renal failure. Perez Gutthann S, Garcia Rodriguez LA, Raiford DS, Duque Oliart A, Ris Romeu J, Arch Intern Med 1996 156 21 2433 2439 10.1001/archinte.1996.00440200041005 8944736 (Pubitemid 26391472)
54. Proton pump inhibitors: pharmacology and rationale for use in gastrointestinal disorders. Richardson P, Hawkey CJ, Stack WA, Drugs 1998 56 3 307 335 10.2165/00003495-199856030-00002 9777309 (Pubitemid 28454260)
55. Upper gastrointestinal toxicity of alendronate. Lowe CE, Depew WT, Vanner SJ, Paterson WG, Meddings JB, Am J Gastroenterol 2000 95 3 634 640 10.1111/j.1572-0241.2000.01835.x 10710050 (Pubitemid 30123895)
56. The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study. Lanza F, Sahba B, Schwartz H, Winograd S, Torosis J, Quan H, Reyes R, Musliner T, Daifotis A, Leung A, Am J Gastroenterol 2002 97 1 58 64 10.1111/j.1572-0241.2002.05446.x 11808969 (Pubitemid 34059764)
57. Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Bauer DC, Black D, Ensrud K, Thompson D, Hochberg M, Nevitt M, Musliner T, Freedholm D, Arch Intern Med 2000 160 4 517 525 10.1001/archinte.160.4.517 10695692 (Pubitemid 30112275)
58. Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal. Rodriguez LAG, Jick H, Lancet 1994 343 8900 769 10.1016/S0140-6736(94)91843-0 7907735 (Pubitemid 24098698)
59. Prevalence of gastrointestinal symptoms in the elderly: a population-based study. Talley NJ, O'Keefe EA, Zinsmeister AR, Melton LJ 3rd, Gastroenterology 1992 102 3 895 901 1537525
60. Positive predictive value of ICD-9 codes in the identification of cases of complicated peptic ulcer disease in the Saskatchewan hospital automated database. Raiford DS, Perez Gutthann S, Garcia Rodriguez LA, Epidemiology 1996 7 1 101 104 10.1097/00001648-199601000-00018 8664388 (Pubitemid 26003854)